Clinical trials of new drugs for Alzheimer disease

LK Huang, SP Chao, CJ Hu - Journal of biomedical science, 2020 - Springer
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, developing effective therapies to …

Role of tau protein in Alzheimer's disease: The prime pathological player

S Muralidar, SV Ambi, S Sekaran, D Thirumalai… - International journal of …, 2020 - Elsevier
Alzheimer's disease (AD) is a prevalently found tauopathy characterized by memory loss
and cognitive insufficiency. AD is an age-related neurodegenerative disease with two major …

The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer's disease

I Vecchio, L Sorrentino, A Paoletti… - Journal of Central …, 2021 - journals.sagepub.com
Alzheimer's disease (AD) is a chronic disabling disease that affects the central nervous
system. The main consequences of AD include the decline of cognitive functions and …

Effects of in vivo conditions on amyloid aggregation

MC Owen, D Gnutt, M Gao, SKTS Wärmländer… - Chemical Society …, 2019 - pubs.rsc.org
One of the grand challenges of biophysical chemistry is to understand the principles that
govern protein misfolding and aggregation, which is a highly complex process that is …

S100 proteins in Alzheimer's disease

JS Cristóvão, CM Gomes - Frontiers in Neuroscience, 2019 - frontiersin.org
S100 proteins are calcium-binding proteins that regulate several processes associated with
Alzheimer's disease (AD) but whose contribution and direct involvement in disease …

[HTML][HTML] A review for the pharmacological effect of lycopene in central nervous system disorders

D Chen, C Huang, Z Chen - Biomedicine & Pharmacotherapy, 2019 - Elsevier
Lycopene is an aliphatic hydrocarbon carotenoid extracted from plants like tomatoes,
papayas, and watermelons. Previous studies have shown that lycopene can exert …

The many faces of astrocytes in Alzheimer's disease

MD Monterey, H Wei, X Wu, JQ Wu - Frontiers in Neurology, 2021 - frontiersin.org
Alzheimer's disease (AD) is a progressive neurodegenerative disease and is the most
common cause of dementia in an aging population. The majority of research effort has …

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

A Cano, P Turowski, M Ettcheto, JT Duskey… - Journal of …, 2021 - Springer
Increasing life expectancy has led to an aging population, which has consequently
increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of …

PROTACs to address the challenges facing small molecule inhibitors

P Martín-Acosta, X Xiao - European journal of medicinal chemistry, 2021 - Elsevier
Small molecule inhibitors of proteins represent important medicines and critical chemical
tools to investigate the biology of the target proteins. Advances in various-omics …

Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer's disease

SA Farr, E Roesler, ML Niehoff… - Journal of …, 2019 - content.iospress.com
Metformin is used for the treatment of insulin resistant diabetes. Diabetics are at an
increased risk of developing dementia. Recent epidemiological studies suggest that …